Search Results - "O’Shea, Anne E"

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis by Carpenter, Elizabeth Lee, Van Decar, Spencer, Adams, Alexandra M, O’Shea, Anne E, McCarthy, Patrick, Chick, Robert Connor, Clifton, Guy Travis, Vreeland, Timothy, Valdera, Franklin A, Tiwari, Ankur, Hale, Diane, Kemp Bohan, Phillip, Hickerson, Annelies, Smolinsky, Todd, Thomas, Katryna, Cindass, Jessica, Hyngstrom, John, Berger, Adam C, Jakub, James, Sussman, Jeffrey J, Shaheen, Montaser F, Yu, Xianzhong, Wagner, Thomas E, Faries, Mark, Peoples, George E

“…BackgroundThe tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast…”
Get full text

Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial by Van Decar, Spencer G., Carpenter, Elizabeth L., Adams, Alexandra M., Chick, Robert C., Clifton, Guy T., Stojadinovic, Alex, Vreeland, Timothy J., Valdera, Franklin A., Tiwari, Ankur, O'Shea, Anne E., McCarthy, Patrick M., Hale, Diane F., Bohan, Phillip M Kemp, Hickerson, Annelies T., Cindass, Jessica L., Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Yu, Xianzhong, Wagner, Thomas, Faries, Mark B., Peoples, George E.

“…•Promoting a targeted host immune response via autologous tumor neoantigen vaccination is an evolving field.•Adjuvant autologous tumor vaccines (TLPO and…”
Get full text

Analysis of Concomitant and Isolated Venous Injury in Military Lower Extremity Trauma by O'Shea, Anne E., Lee, Christina, Kauvar, David S.

“…The implications of major venous injury to the lower extremity are not well established. We aimed to determine the significance of concomitant and isolated…”
Get full text

The role of self‐reliance and denial in the help‐seeking process for eating disorders among university students by Fabry, Esme, Fassnacht, Daniel B., Ford, Rachael, Burns, Nicholas R., O'Shea, Anne E., Ali, Kathina

“…Objective This study investigated how self‐reliance and denial influence the relationship between help‐seeking attitudes and behaviour. Method Australian…”
Get full text

ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma by O’Shea, Anne E., Carpenter, Elizabeth L., Nelson, Daniel W., Vreeland, Timothy J.

Get full text

Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival by O’Shea, Anne E., Bohan, Phillip M. Kemp, Carpenter, Elizabeth L., McCarthy, Patrick M., Adams, Alexandra M., Chick, Robert C., Bader, Julia O., Krell, Robert W., Peoples, George E., Clifton, Guy T., Nelson, Daniel W., Vreeland, Timothy J.

“…Background Neoadjuvant chemotherapy (NAC) or chemoradiation (NAC+XRT) is incorporated into the treatment of localized pancreatic adenocarcinoma (PDAC), often…”
Get full text

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention by O'Shea, Anne E., Valdera, Franklin A., Ensley, Daniel, Smolinsky, Todd R., Cindass, Jessica L., Kemp Bohan, Phillip M., Hickerson, Annelies T., Carpenter, Elizabeth L., McCarthy, Patrick M., Adams, Alexandra M., Vreeland, Timothy J., Clifton, Guy T., Peoples, George E.

“…Rapamycin inhibits the mechanistic (formally mammalian) target of rapamycin (mTOR), an evolutionarily conserved intracellular kinase that influences activation…”
Get full text

AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence by McCarthy, Patrick M, Clifton, G Travis, Vreeland, Timothy J, Adams, Alexandra M, O'Shea, Anne E, Peoples, George E

“…HER2 is a prevalent growth factor in a variety of malignancies, most prominently breast cancer. Over-expression has been correlated with the poorest overall…”
Get more information

The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy by Carpenter, Elizabeth L., Van Decar, Spencer G., McCarthy, Patrick M., Valdera, Franklin A., Adams, Alexandra M., O'Shea, Anne E., Smolinsky, Todd, Thomas, Katryna, Clifton, Guy T., Newhook, Timothy E., Peoples, George E., Nelson, Daniel W., Vreeland, Timothy J.

“…Background The benefit of adjuvant therapy (AT) remains unclear in pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and surgical…”
Get full text

Examination of the difficulties in emotion regulation scale and its relation to disordered eating in a young female sample by Cooper, Jane L., O'Shea, Anne E., Atkinson, Melissa J., Wade, Tracey D.

“…Objective Difficulties with emotion regulation is considered an important maintaining factor of disordered eating. One of the most commonly used measures of…”
Get full text

Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder Cancer by Kemp Bohan, Phillip M., O’Shea, Anne E., Ellis, Oriana V., Chick, Robert C., Clem, Alex M., Kirby, Derek T., Bader, Julia O., Newhook, Timothy E., Clifton, G. Travis, Tzeng, Ching-Wei D., Nelson, Daniel W., Vreeland, Timothy J.

“…Introduction Lymphadenectomy (LND) is recommended following surgical resection of ≥ T1b gallbladder cancer (GBC). However, frequency and stage-specific…”
Get full text

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial by Adams, Alexandra M., Carpenter, Elizabeth L., Clifton, Guy T., Vreeland, Timothy J., Chick, Robert C., O’Shea, Anne E., McCarthy, Patrick M., Kemp Bohan, Phillip M., Hickerson, Annelies T., Valdera, Franklin A., Tiwari, Ankur, Hale, Diane F., Hyngstrom, John R., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser F., Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B., Peoples, George E.

“…Background A randomized, double-blind, placebo-controlled phase 2b trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was conducted in…”
Get full text

Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters by Valdera, Franklin A., O'Shea, Anne E., Smolinsky, Todd R., Carpenter, Elizabeth L., Adams, Alexandra A., McCarthy, Patrick M., Tiwari, Ankur, Chick, Robert C., Kemp‐Bohan, Phillip M., Van Decar, Spencer, Thomas, Katryna K., Bader, Julia O., Peoples, George E., Clifton, Guy T., Stojadinovic, Alex, Nelson, Daniel W., Vreeland, Timothy J.

“…Introduction Adjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a…”
Get full text

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer by O’Shea, Anne E., Clifton, Guy T., Peoples, George E.

Get full text

Understanding stigma in the context of help-seeking for eating disorders by Wall, Prudence L, Fassnacht, Daniel B, Fabry, Esme, O'Shea, Anne E, Houlihan, Catherine, Mulgrew, Kate, Ali, Kathina

“…Stigma is a complex construct and its association with help-seeking among those experiencing eating disorders is not well understood. Rates of help-seeking are…”
Get full text

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials by McCarthy, Patrick M, Valdera, Franklin A, Smolinsky, Todd R, Adams, Alexandra M, O'Shea, Anne E, Thomas, Katryna K, Van Decar, Spencer, Carpenter, Elizabeth L, Tiwari, Ankur, Myers, John W, Hale, Diane F, Vreeland, Timothy J, Peoples, George E, Stojadinovic, Alex, Clifton, Guy T

“…Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in…”
Get full text

Thymic adenocarcinoma presenting as an incidental mediastinal mass by O'Shea, Anne E, Nissen, Alexander P, Bowen, Donnell K, Barnett, Taylor L, Gustafson, Joshua D

“…Abstract Background Primary thymic adenocarcinoma represents an exceptionally rare malignancy, for which the cornerstone of therapy is margin-negative…”
Get full text

Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ by O'Shea, Anne E, Clifton, Guy T, Qiao, Na, Heckman-Stoddard, Brandy M, Wojtowicz, Malgorzata, Dimond, Eileen, Bedrosian, Isabelle, Weber, Diane, Garber, Judy E, Husband, Alexander, Pastorello, Ricardo, Lee, J Jack, Hernandez, Mike, Liu, Diane D, Vornik, Lana A, Brown, Powel H, Alatrash, Gheath, Peoples, George E, Mittendorf, Elizabeth A

“…NeuVax is a vaccine comprised of the HER2-derived MHC class I peptide E75 (nelipepimut-S; [NPS]) combined with granulocyte-macrophage colony-stimulating factor…”
Get full text

Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression by Kemp Bohan, Phillip M, Chick, Robert C, O'Shea, Anne E, Vreeland, Timothy J, Hickerson, Annelies T, Cindass, Jessica L, Ensley, Daniel C, Hale, Diane, Clifton, Guy T, Sohn, Vance Y, Thompson, Jr, Ian M, Peoples, George E, Liss, Michael A

“…No approved medical therapies prevent progression of low-grade prostate cancer. Rapamycin inhibits cell proliferation and augments immune responses, producing…”
Get full text

Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma by McCarthy, Patrick M, Rendo, Matthew J, Uy, Matthew D, Adams, Alexandra M, O'Shea, Anne E, Nelson, Daniel William, Fenderson, Joshua L, Cebe, Katherine M, Krell, Robert W, Clifton, Guy T, Peoples, George E, Vreeland, Timothy J

“…Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of…”
Get full text